|
Code
|
03260
|
|
MA number
|
EU/1/99/126/003
|
|
Product Form:
|
plv iol 4x25 mg + 4x1 ml solv. (liek.inj.skl.+striek.inj.napl.skl.)
|
|
MA Status:
|
E - Valid centralised marketing authorisation
|
|
Type of procedure:
|
EU
|
|
MAH, country:
|
Pfizer Europe MA EEIG, Belgium
|
|
Therapeutic Class:
|
29 - ANTIRHEUMATICA, ANTIPHLOGISTICA, ANTIURATICA
|
|
ATC:
|
| L |
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS |
| L04 |
Immunosuppressants |
| L04A |
Immunosuppressants |
| L04AB |
Tumor necrosis factor alpha (TNF-alpha) inhibitors |
| L04AB01 |
Etanercept |
|
|
Shelf life:
|
48 |
|
Route of admin.:
|
Subcutaneous use
|
European Medicines Agency's database
